| Autor: |
Singh, Gagandeep, Al-Fahad, Dhurgham, Al-Zrkani, Mrtatha K., Chaudhuri, Tapan K., Soni, Hemant, Tandon, Smriti, Narasimhaji, Cheemalapati Venkata, Azam, Faizul, Patil, Rajesh |
| Zdroj: |
Journal of Biomolecular Structure and Dynamics; October 2024, Vol. 42 Issue: 15 p8184-8201, 18p |
| Abstrakt: |
AbstractBreast cancer is one of the most prevalent and malignant cancers in women. Most breast cancer patients show overexpression of the HER2 protein. The current study focused on identifying potent inhibitors of HER2 using a structure-based drug design approach. Prefiltered compounds from the Drugbank and the ZINC database were docked on HER2 protein using the FlexX docking tool of LeadIT. The docking study identified the 12 best molecules that interacted strongly with the active site of HER2 and also fulfilled the ADMET parameters. The complexes of these compounds with HER2 were further subjected to molecular dynamics simulation using GROMACS 2021.4, followed by the end-state MMGBSA binding energy calculations. The RMSD analysis was conducted to study the conformational changes, which revealed stability throughout the 100 ns simulation period. The local flexibility and dynamics of the simulated ligand-protein complexes were studied using RMSF analysis. The values of the radius of gyration were computed to analyze the compactness of HER2. The MMGBSA analysis provided insights into the energetic aspects of the system. The compound DB15187 emerged as the most potent candidate, showing MMGBSA-computed binding energy of −63.60 ± 3.39 kcal/mol. The study could help develop targeted therapies for HER2-positive breast cancer.Communicated by Ramaswamy H. Sarma |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
